Wockhardt Limited files SEBI Regulation 31(4) disclosure on substantial acquisition
Wockhardt Limited, a listed pharmaceutical company, has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 to the National Stock Exchange. This disclosure is mandatory when a party acquires 25% or more of voting capital, or has already acquired 25% and acquires a further 2% in any financial year (creeping acquisition). The filing does not specify the acquirer, consideration, or shareholding threshold crossed based on the article excerpt; the full details are contained in the NSE-filed PDF document dated 30 June 2026.
Why it mattersRegulation 31(4) disclosure signals either a trigger of the 25% threshold requiring an open offer, or a concert-party or creeping acquisition requiring regulatory notification-partner must obtain the full disclosure document to determine acquirer identity, price, shareholding crossed, and open offer timeline obligations.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Wockhardt Limited Disclosure Filing · official
- SEBI - Takeover Regulations Portal · official
- NSE - Corporate Actions & Disclosures Portal · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026